NASDAQ: FULC
Fulcrum Therapeutics Inc Stock Ownership - Who owns Fulcrum Therapeutics?

Insider buying vs selling

Have Fulcrum Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Alex SapirPresident Chief Executive Officer2024-07-03150,000$3.27
$490.50kBuy
Greg TourangeauPrincipal Accounting Officer2024-05-07236$7.76
$1.83kSell

1 of 1

FULC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FULC insiders and whales buy or sell their stock.

FULC Shareholders

What type of owners hold Fulcrum Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP31.92%17,229,099$56.68MInsider
Ra Capital Management LP18.95%10,229,099$33.65MInstitution
Mark J. Levin11.20%6,046,425$19.89MInsider
Tcg Crossover Management LLC9.73%5,250,000$17.27MInstitution
Blackrock Inc9.58%5,169,429$17.01MInstitution
Nantahala Capital Management LLC8.85%4,779,708$15.73MInstitution
Suvretta Capital Management LLC6.18%3,338,466$10.98MInstitution
Vanguard Group Inc6.02%3,249,607$10.69MInstitution
Adage Capital Partners GP LLC5.56%3,000,000$9.87MInstitution
Third Rock Ventures III LP4.63%2,499,343$8.22MInsider

1 of 3

FULC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FULC60.93%39.07%Net Buying
ELDN55.81%44.19%
GNFT0.41%0.00%
TVGN1.31%85.95%Net SellingNet Selling
CDXS46.56%53.44%Net BuyingNet Buying

Fulcrum Therapeutics Stock Ownership FAQ

Who owns Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ: FULC) is owned by 95.66% institutional shareholders, 61.33% Fulcrum Therapeutics insiders, and 0.00% retail investors. Ra Capital Management LP is the largest individual Fulcrum Therapeutics shareholder, owning 17.23M shares representing 31.92% of the company. Ra Capital Management LP's Fulcrum Therapeutics shares are currently valued at $56.68M.

If you're new to stock investing, here's how to buy Fulcrum Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.